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ABSTRACT 
Background: Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of 
the central nervous system and a leading cause of neurological disability in young adults. 
Magnetic resonance imaging (MRI) has improved the diagnostic process in MS, but has also 
led to incidental MS-like findings. The growing therapeutic arsenal and the variable clinical 
expression of MS makes MRI important for evaluating treatment response and advanced 
volumetric measurements are common endpoints in MS treatment trials. More feasible MRI 
measurements are, however, needed in order to implement quantitative MRI biomarkers in 
clinical practice, where they may aid in individualizing treatment and care for MS patients.  
Purpose: The aim of this thesis is to describe neuroradiological aspects of MS, from its 
earliest signs to late stages, by describing the frequency and significance of incidental MRI 
findings suggestive of MS, and by studying corpus callosum atrophy as a biomarker for 
cognitive and physical disability in MS over a wide range of disease duration.  
Study I, a systematic review, showed that incidental brain MRI findings suggestive of MS 
without typical MS symptoms, and with no better explanation of the findings, are of clinical 
importance. This entity is preferably called radiologically isolated syndrome (RIS) and 
persons with RIS often have subclinical cognitive impairment and radiological measurements 
similar to those seen in MS. RIS progresses radiologically in a majority of cases and about 
one third of the patients are diagnosed with MS over a mean follow-up time of five years.  
Study II, a retrospective cohort study, showed that RIS is an uncommon finding. In a yearly 
sample of the brain MRI examinations of 2105 patients at Karolinska University Hospital, 
only one case of RIS was found (0.05%). The patient later developed clinically active MS.  
Study III compared the performance and feasibility of the two leading radiological methods 
for assessing corpus callosum atrophy, corpus callosum area (CCA) and corpus callosum 
index in a cross-sectional evaluation of the participants in Study IV. Both measurements 
could be obtained in less than a minute with excellent repeatability. CCA had the strongest 
correlations with cognitive and physical disability, and was most accurate in differentiating 
patients from controls and relapse-remitting MS from progressive forms of MS. 
Study IV was a 17-year longitudinal cohort study of 37 MS patients that were evaluated 
clinically, neuropsychologically and radiologically, and a matched healthy control group. The 
disease durations spanned over five decades, reflecting a panorama of early to late stages of 
the disease. The corpus callosal atrophy rate decreased with increasing disease duration. The 
normalized corpus callosum area was correlated with cognitive (r = 0.79, p < 0.001) and 
physical (r = -0.55, p < 0.001) disability, outperforming commonly used volumetric methods.  
Conclusions: RIS is a rare but clinically important condition that in many cases constitutes 
preclinical MS. CCA is a feasible measurement of corpus callosum atrophy for MS research 
and clinical practice, and outperforms classical volumetric measurements as a biomarker for 
cognitive and physical disability in MS.   
SAMMANFATTNING 
Bakgrund: Multipel skleros (MS) är en kronisk inflammatorisk och degenerativ sjukdom 
som drabbar hjärna och ryggmärg. Skadornas utbredning varierar, vilket leder till att 
symtomen kan skilja sig påtagligt åt mellan individer. Undersökning med magnetkamera 
(MR) kan påvisa tecken till MS och bidrar till förbättrad MS-diagnostik, men också till 
bifynd som radiologiskt liknar MS hos personer som undersöks av andra skäl. De senaste två 
decennierna har behandlingsmöjligheterna vid MS förbättrats, vilket ökat betydelsen av MR 
för att utvärdera terapieffekten. Avancerade MR-volymmått av hjärnan har därför kommit att 
bli viktiga utfallsmått i läkemedelsstudier. MR-mått måste dock vara praktiska för att kunna 
tillämpas i kliniskt arbete, där de kan bidra till individanpassad behandling vid MS.  
Syfte: Den här avhandlingen syftar till att beskriva neuroradiologiska aspekter av MS, från 
sjukdomens tidigaste tecken till dess sena stadier, genom att beskriva förekomsten och 
betydelsen av oväntade MR-fynd som liknar MS, och genom att studera atrofi av hjärnbalken 
(corpus callosum) som markör för fysisk och kognitiv funktionsnedsättning vid MS. 
Studie I, en systematisk översiktsartikel, visade att MR-bifynd som liknar MS hos personer 
som inte har typiska MS-symtom är kliniskt betydelsefulla. Personer med detta tillstånd 
(lämpligen kallat radiologiskt isolerat syndrom, RIS) uppfyller inte kriterierna för MS, men 
har ofta kognitiva funktionsnedsättningar och MR-mätvärden som liknar de som ses vid MS. 
Hos de flesta ses en progress av MR-fynden och en tredjedel utvecklar MS inom fem år. 
Studie II, en retrospektiv kohortstudie, visade att RIS är ett ovanligt tillstånd. Vid en 
genomgång av samtliga MR-undersökningar som utfördes under ett års tid vid Karolinska 
Universitetssjukhuset i Huddinge återfanns endast 1 fall av RIS bland 2105 personer (0,05%).  
Studie III jämförde två radiologiska metoder för mätning av atrofi i corpus callosum vid MS. 
De två metoderna, corpus callosum area (CCA) och corpus callosum index (CCI), 
tillämpades i patientgruppen som beskrivs i Studie IV. Båda metoderna kunde mätas inom en 
minut med utmärkt reproducerbarhet. CCA var starkast korrelerat till kognitiv och fysisk 
funktionsnedsättning vid MS. CCA var även mest tillförlitligt i att skilja MS-patienter från 
friska kontrollpersoner och i att skilja MS med progressivt och skovvist förlopp.  
I Studie IV följdes 37 MS-patienter neurologiskt, neuropsykologiskt och radiologiskt under 
17 år. Patienternas sjukdomsdurationer omfattade fem decennier, avspeglande tidiga till sena 
faser av MS. Hjärnbalksatrofin avtog med tiden och normaliserat CCA var starkt kopplat till 
kognitiv funktionsnedsättning och måttlig korrelerat till fysisk funktionsnedsättning. Dessa 
korrelationer var starkare än motsvarande samband för volymmått av hjärnvävnaderna. 
Slutsatser: RIS är ett ovanligt men kliniskt betydelsefullt tillstånd som i många fall utgör en 
preklinisk fas av MS. CCA är ett praktiskt mått för att bedöma hjärnbalksatrofi, vilket 
presterar bättre än CCI och volymmått av hjärnan som markör för kognitiv och fysisk 
funktionsnedsättning vid MS. CCA kan således vara ett lämpligt mått för MS-forskning och 
kliniskt arbete.   
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1 INTRODUCTION  
1.1 MULTIPLE SCLEROSIS  
1.1.1 Overview and historical background  
Multiple sclerosis (MS) is a common chronic immune-mediated disease that affects the 
central nervous system (CNS), leading to neurological dysfunction.1 The name originates 
from the fact that the disease causes damage at multiple locations in the brain and spinal cord 
where the inflammatory lesions leave sclerotic scars.2 In Swedish, MS can be translated as 
“många ärrhärdar” or more loosely as “Många Skadeställen”.3  
MS mainly affects young otherwise healthy persons with a mean age at MS onset of 29 years. 
The disease often leads to both physical and cognitive disability, but the disease course is 
hard to predict as some patients will have a benign course, while others will have a relentless 
disease progression. In either case, MS has significant effects on both an individual and a 
community level, where the disease is estimated to cause costs of 9 billion euros per year in 
the European Union alone.2  
The first comprehensive descriptions of the disease stems from the late 18th century, and early 
pathological descriptions came in the first half of the 19th century.4,5 The disease is considered 
to have been characterized as a separate disease entity by the French physician Jean-Martin 
Charcot in 1868.6 In the near one and a half century that has passed since Charcot’s 
description of the disease, there has been ever increasing research interest in MS, not least 
after the introduction of effective disease-modifying therapies (DMT) and the subsequent 
increasing therapeutic arsenal. These research efforts have dramatically improved our 
knowledge and understanding of the disease. A summary of the current knowledge base with 
focus on neuroradiological aspects is presented below.  
1.1.2 Epidemiology  
Globally, around 2.5 million people have MS, but there are large variations in prevalence and 
incidence of MS across different regions, as illustrated in Figure 1.7 MS is a relatively 
common disease in Scandinavia, and Sweden has one of the highest reported frequencies of 
MS with an incidence of 10.2 per 100,000 person-years and a prevalence of 189 per 100,000 
inhabitants.8,9 There is also a prominent sex difference in MS, where women are more than 
twice as likely to be affected by MS. In Sweden, the current female to male ratio is 2.5.8 The 
prevalence of MS is increasing, which is mainly attributed to increases in life expectancy.10  
The skewed geographical distribution of MS has been attributed to a combination of genetic 
and environmental factors and has been the focus of numerous epidemiological studies trying 
to better understand MS pathophysiology. It has for example been shown that close relatives 
of MS patients have a higher risk of developing MS than the general population. 
Monozygotic twins of MS patients have a lifetime risk of developing MS around 30%, while 
first degree relatives have a risk of around 2-5% and half-siblings around 1%,11 which can be 
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compared to the general population risk of around 0.2% in Sweden.8 Genetic studies have so 
far uncovered more than 100 risk gene variants for MS, but many of these variants are 
common in the general population and each variant only carries a modestly increased risk for 
MS. Interestingly, all of the identified genes are associated with immunity.12 
Figure 1. National prevalence of MS per 100,000 inhabitants. Data based on a WHO survey in 2004, 
updated by the MS International Federation in 2013.13  
The importance of environmental factors is highlighted by the fact that the risk of developing 
MS changes with migration. The MS risk becomes intermediate of that attributed to the 
region of origin and the new region, with a greater adaption to the new region’s risk when 
moving before adolescence.14 A phenomenon that has gained much interest is that the 
prevalence of the disease follows a North and South gradient from the equator, with 
increasing prevalence closer to the poles.10,15 This has also been shown in Sweden, where the 
prevalence of MS increases with 1.0–1.5% per degree of north latitude.8 Solar ultraviolet 
radiation, and secondarily vitamin D3-levels that are dependent on skin exposure to sunlight 
as well as dietary intake of vitamin D, have therefore been proposed as protective factors.16  
An umbrella review of environmental risk factors for MS recently found that among 44 
studied possible risk factors (including comorbidities, infections, trauma, vaccinations and 
toxic substances), only three risk factors were supported by strong epidemiological evidence: 
immunoglobulin G (IgG) seropositivity for Epstein-Barr virus (EBV) nuclear antigen 
(random effects odds ratio, OR, 4.5), infectious mononucleosis (OR 2.2) and smoking (OR 
1.5).17 Although the association of MS and EBV exposure is significant, it is important to 
remember that a large majority of the healthy adult population are seropositive for EBV.18  
  3 
1.1.3 Etiology and pathophysiology 
The cause of MS remains unknown, but there is a growing body of knowledge regarding the 
pathophysiology of MS, which is likely to assist in identifying its genesis, although this 
discovery may continue to elude us for a long time ahead.  
A majority of the nerve fibers, axons, in the brain 
are insulated by oligodendrocytes with a substance 
called myelin that consists of lipids (42%), water 
(40%) and proteins (18%).19 In MS, the myelin is 
damaged, impeding nerve conduction and 
triggering neurological symptoms.2 The histo-
pathological hallmarks of MS are demyelination 
and perivenous inflammation, illustrated in Figure 
2, with axonal loss, gliosis and neuronal 
degeneration.20 The demyelination is caused by 
both immunological and neurodegenerative 
processes, but it is still debated which of these two 
components that are the primary and secondary 
driving force of the disease.21  
MS is considered to be driven by self-reactive mononuclear cells (monocytes, B- and T-cells) 
which migrate across the blood brain barrier into the CNS.2 Although T-cells have mainly 
been in focus, the importance of B-cells is highlighted by intrathecal IgG production, the 
clinical response to anti-CD20 therapies and the relationship of meningeal follicles with 
cortical lesions.23,24 Intriguingly, there is large inter-individual heterogeneity in the 
inflammatory response seen in MS lesions microscopically with four different 
histopathological patterns.20 It is, however, unclear what implications these findings may 
have for diagnosis, subtyping and treatment of MS.  
1.1.4 Diagnosis  
There is no pathognomonic feature of MS, nor is there an absolute diagnostic test for MS. 
The diagnosis therefore relies on diagnostic criteria demonstrating that the CNS is affected by 
the disease at two different locations, called dissemination in space (DIS), at two different 
points in time, called dissemination in time (DIT).25 
The MS diagnostic criteria are constantly being revised according to new research findings in 
order to facilitate and increase the accuracy of MS diagnostics. In 1965, Schumacher et al. 
introduced the first modern criteria, which were solely based on clinical findings.26 In 1983, 
Poser et al. incorporated paraclinical methods such as cerebrospinal fluid (CSF) analysis, 
evoked potentials and neuroimaging. Brain and spinal MRI lesions were integrated as a key 
diagnostic feature in the MS diagnostic criteria in 2001 by McDonald et al.,27,28 and the 
McDonald criteria have since been revised in 2005 and in 2010.25,29  
Figure 2. Microscopic image with Luxol 
fast blue staining of a MS lesion showing 
perivenous inflammation (arrow) and 
demyelination (whiter area).22 Image 
courtesy of professor Stephen DeArmond. 
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Clinically isolated syndrome (CIS) is a distinct entity where there is only clinical evidence of 
one symptomatic episode suggestive of MS and yet no evidence of DIT. CIS has been 
important as a pre-diagnostic stage of MS, but the prevalence of CIS is expected to decrease 
with the use of the latest McDonald criteria as a single MRI scan can now demonstrate both 
DIS and DIT.25,30 The constantly adapting MS criteria mean that longitudinal MS research is 
studying a moving target, complicating comparisons with older studies.31   
1.1.5 Clinical manifestations and subtypes  
The clinical expression of MS is variable as any part of the CNS can be affected.1 Frequent 
symptoms include sensory disturbances (numbness, tingling, pain, itching, vertigo), visual 
problems, affected motor abilities (walking difficulties, muscle spasms, tremor) and 
autonomic functions (sexual difficulties, bladder and bowel dysfunctions), as well as more 
diffuse symptoms (fatigue, depression, cognitive impairment).1  
MS is classically divided in four subtypes with different disease courses,32 illustrated in 
Figure 3. The most common form (85%) is relapse-remitting MS (RRMS), where there are 
acute episodes of worsening with full or partial recovery, interspersed with a period of 
remission until the next relapse. A relapse usually lasts less than a few months and the mean 
number of relapses is 0.4 per year.2 Typically, relapses eventually become less frequent with 
accumulating disability, and about two third of RRMS patients will go on to a secondary 
progressive phase (SPMS) with a steady decline in neurological functions after 15-20 years.33  
Figure 3. Illustration of the disease course of the four classical MS subtypes. The drastic changes in 
physical disability represent relapses.  
 
In 15% of MS patients there is a progressive decline from onset called primary progressive 
MS (PPMS), or progressive-relapsing MS (PRMS) if there are superimposed relapses.32 
PPMS patients have a more even female to male ratio and are on average 10 years older at 
onset than RRMS patients. PPMS typically has a faster disease progression than RRMS, why 
patients with PPMS and SPMS will be about the same age when they reach important 
disability milestones.21 The diagnostics of PPMS is more complicated than for RRMS as it is 
a less common presentation and does not provide relapses to prove DIT. Adding to the 
complexity is the higher age of the patients, leading to more comorbidities and a higher 
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incidence of other neurodegenerative diseases. The criteria for PPMS require one year of 
progressive worsening without remission and supportive evidence by two of the following: 
≥1 brain lesions (periventricular, juxtacortical or infratentorial), ≥2 spinal cord lesions or 
abnormal CSF findings (oligoclonal bands, elevated IgG index).25 
While the subtypes are helpful in giving a broad understanding of disease progression, this 
stratification does not fully reflect the individual clinical expression of MS. In 2014, a 
complementary categorization was introduced where the combination of clinical relapses and 
imaging findings are used to describe the disease as active/non-active and as having 
progression/no progression. This update has eliminated the need for the rarely used PRMS 
subtype, as it is now described as PPMS with disease activity.30  
Similarly to the varying symptomatology, the disease activity and progression is highly 
individual, making it hard to predict the clinical outcome.2 Clinical predictors associated with 
a poor prognosis are incomplete recovery after the first episode, a short remission until the 
first relapse and bladder/bowel disturbances at onset.34  
1.1.6 Treatment 
The treatment of MS has been revolutionized in the last two decades. The first effective 
disease-modifying therapies (DMTs) were introduced in the mid-1990s and since then the 
number of available treatments has increased substantially with many new DMT classes.35 
Early treatment has been supported by the fact that axonal damage is closely related to 
inflammation and occurs early in MS, and that the radiological and clinical progression of 
CIS can be delayed by DMTs.36 It has also been shown that early treatment decelerates the 
longterm progression of RRMS,37 and reduces the mortality rate 20 years later with 46%.38  
Treatment options in RRMS have recently been further improved by the introduction of the 
first oral therapies.39 Autologous hematopoietic stem cells transplantation has shown 
remarkable results in the treatment of aggressive MS.40,41 There is also hope for finding 
effective therapy in progressive MS as treatment with statins, which are believed to have 
immunomodulatory effects, has shown promising results in reducing brain atrophy.42 This 
expanded therapeutic arsenal does, however, complicate the treatment choice in individual 
patients as the treatment efficacies and side effects differ. Neuroradiological biomarkers can 
therefore play an important role in aiding neurologists to tailor treatment for their patients.43  
1.1.7 Clinical measurements of disability 
MS is the leading non-traumatic cause of neurological disability in young adults in Europe 
and the United states, which affects the patients’ health-related quality of life.1,2 In the natural 
progression of MS, patients typically need a cane when walking after two decades and a 
wheelchair after three decades of disease duration.2  
The physical disability in MS is overt and there are numerous methods to quantify it. The 
consistently most used rating scale is the expanded disability status scale (EDSS) that was 
introduced by Kurtzke et al. in 1983.44 It is a 10-grade scale of physical disability, illustrated 
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in Figure 4. Despite its wide use in clinical 
trials and MS research, the scale does have 
several limitations. The scoring is based on 
subjective neurological assessment, with 
poor reproducibility, and the scale is non-
linear, which causes statistical limitations.45  
The major argument against EDSS is that it does not reflect non-physical MS disability. 
There has hence been a lot of effort put into finding suitable replacement scales. The most 
commonly used alternative is the multiple sclerosis functional composite (MSFC), which is a 
multi-dimensional scale reflecting ambulation (25 m timed walk), hand function (9 hole peg 
test) as well as attention and information processing speed (paced auditory serial addition test, 
PASAT). Although MSFC solves many of the issues of EDSS, it has not yet come to replace 
EDSS, probably due to its limited practicability with 30 minutes of testing time.45  
Cognitive impairment is common in MS (43-70%) and is present even in the earliest stages of 
the disease. Although the cognitive deficits can be subtle, they are disabling and affect the 
patients’ health-related quality of life. The most consistently reported cognitive deficits 
include memory and visual learning disturbances, affected sustained and divided attention, 
information processing speed and abstract reasoning. Meanwhile, general intelligence and 
language functions remain relatively intact.46 
The two most recognized neuropsychological test batteries are the brief repeatable battery of 
neuropsychological tests and the minimal assessment of cognitive function in MS. These take 
up to 1.5 hour to administer,47 which is why recommendations have been stipulated for brief 
cognitive monitoring in order to make it more practical. The primary recommended test is the 
symbol digit modalities test (SDMT), measuring information processing speed.48 In SDMT, 
the participant deciphers symbols into numbers with the help of a numerical key during 90 
seconds. The test has good reproducibility49 and is sensitive to cognitive decline as it reflects 
a neuroanatomically widely dispersed frontoparietal network.50,51 We have chosen to focus on 
SDMT in our studies, which is in line with the aforementioned recommendations. In order to 
more globally detail cognitive functioning, we have also administered three complimentary 
tests for which the main concepts presented below:  
• FAS, a phonemic verbal fluency test, reflecting an anatomically well defined 
frontotemporal function,52 as the participant is asked to name as many words as 
possible during one minute starting with each of the letters F, A and S.53  
• Rey-Osterrieth complex figure test - copy, assessing visuospatial constructional 
ability located in the parietal lobes and executive functions located prefrontally.54 
• Rey auditory verbal learning test, evaluating verbal learning and memory associated 
with the medial temporal lobe. The participant is presented with 15 words and asked 
to repeat them, which is iterated five times (encoding). After 30 minutes the 
participant tries to recall as many words as possible (free retrieval), which involves 
additional prefrontal regions.55  
0     1     2     3    4     5     6     7    8     9   10 
Normal neurological 
examination  
No disability  
Cane 
Wheelchair 
   Bedridden 
Death 
Figure 4. The expanded disability status scale. 
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1.2 MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS  
MRI it the most important imaging method in MS due to its 
excellent tissue contrast, which exceeds the capabilities of 
computed tomography (CT), not least in the posterior fossa 
that is a common location for MS pathology. MRI’s 
superiority for MS lesion detection in comparison with CT 
was reported as early as in the first published application of 
MRI in MS in 1981,56 as shown in Figure 5. Overall, MRI 
can visualize positive findings in more than 95% of MS 
patients.57 The key concepts of MRI in the diagnostic 
investigation, treatment surveillance, clinical trials and for 
increasing our pathophysiological understanding of MS are 
presented below. 
1.2.1 Background and basic MRI physics 
MRI is an advanced non-invasive imaging technique that is the gold standard imaging 
modality in many neurological disorders. The underlying concepts have been awarded several 
Nobel prizes.58 One of the major advantages with MRI is that, unlike CT, it is not based on 
ionizing radiation. The imaging is instead constructed by using the interaction between 
atomic nuclei in the imaged subject and radio waves under the influence of strong magnetic 
fields. Clinical MRI typically operates at magnetic field strengths of 1.5 or 3.0 Tesla (T), 
equivalent of up to 60,000 times the strength of Earth’s magnetic field.59  
Some atomic nuclei have an inherent magnetic property called spin and basically act as 
“mini-magnets”. The most abundant atomic nuclei with a spin in the body are the hydrogen 
atoms, also called protons. The protons align parallel or antiparallel with the main magnetic 
field in the MRI scanner and spin around their own axis. A few more protons align parallel 
with the main field (10 per million per 1.5 T), causing a small magnetic vector that can be 
imaged under the right circumstances. By applying magnetic field gradients and radio waves 
with the right frequency (resonating with the protons’ spin) the direction of the protons can be 
altered. The radio waves and gradient fields are collectively called pulse sequences and are 
used to “tip” the magnetic vector so that it can be measured with metallic coils acting as 
antennas. Different MRI contrast weightings are obtained by manipulating the net magnetic 
vector and measuring the effects, resulting in excellent soft tissue contrast and high sensitivity 
for pathological changes.59  
1.2.2 Conventional MRI sequences  
Standard MRI sequences in MS include PD-, T1- and T2-weighted images along with fluid-
attenuated inversion recovery (FLAIR) and contrast-enhanced T1-weighted images. An 
example of these tissue contrasts is illustrated in Figure 6. The improved signal-to-noise ratio 
that 3 T provides compared to 1.5 T can generally be used to improve the lesion contrast, 
spatial resolution and/or reduce the acquisition time.  
 
Figure 5. The first published 
brain MRI in MS visualizing 
multiple lesions (arrows) in an 
18-year-old female with MS.56 
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Proton density (PD) weighted images simply reflect the amount of 
signal that is obtained from the tissues, as the signal is proportional 
to the number of protons.59 In clinical practice, this weighting is 
suitable for detecting lesions in areas that can be prone to image 
artifacts on other sequences, i.e. mainly to detect or confirm 
infratentorial and spinal lesions.  
T2-weighted images are sensitive to water content, for instance the 
CSF. MS lesions are typically seen as hyperintensities on T2-
weighted images due to increased water content in edema or loss of 
normal tissue that is replaced by CSF. The findings are, however, 
not specific for MS. Some of these lesions will also eventually 
disappear.57 By adding an inversion pulse to reduce the signal from 
free water such as CSF, a T2-FLAIR is obtained. This increases 
the sensitivity for MS lesions and FLAIR images are therefore 
important in clinical practice.60 FLAIR images are, however, prone 
to artifacts, why lesions generally have to be confirmed on other 
sequences (i.e. PD-, T1- or T2-weighted images).57 Three-
dimensional (3D) acquisition of the FLAIR images may increase 
lesion sensitivity additionally.61,62  
T1-weighted images are often used to confirm the location of MS 
lesions, but only 10-30% of T2-hyperintense lesions are also seen 
on traditional T1 sequences. The contrast in T1-weighted images is 
to a large extent dependent on the lipid content of the tissues, and 
the image intensity is reduced as the fatty myelin is damaged in 
MS, displayed as low signal (hypointensities) in the T1-weighted 
images. MS lesions with low T1-signal compared to the normal-
appearing white matter are referred to as “black holes” and are 
more strongly correlated to axonal loss and physical disability than 
MS lesions only seen on T2-weighted images.60,63 3D T1-weighted 
sequences such as magnetization-prepared rapid acquisition with 
gradient echo (MPRAGE) add the beneficial possibilities of multi-
planar reconstructions and volumetric analysis of the brain.64 The 
proportion of lesions that are seen on T1-weighted images increase 
with MPRAGE sequences and the field strength.65  
Contrast-enhancement after intravenous administration of 
Gadolinium-based contrast media is most commonly imaged on 
T1-weighted images where the paramagnetic Gadolinium shortens 
T1-relaxation times, and increases the signal intensity.59 The blood 
brain barrier may be disrupted if there is active inflammation in the 
CNS, leading to increased permeability for cells, macromolecules 
Figure 6. Axial non-contrast 
MRI in a 49-year-old male MS 
patient. PD, T2, FLAIR and T1 
indicates image type/weighting. 
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and contrast media. Drastic changes in signal intensity between native and contrast-enhanced 
images are thus strongly indicative of active inflammation.60  
Most MS lesions initially go through a phase with contrast-enhancement that typically 
resolves within 2-6 weeks.66,67 The sensitivity for contrast-enhancing lesions is highly 
dependent on the dose and the timing of imaging. Although higher contrast media doses 
result in more detected contrast-enhancing lesions, standard doses are generally 
recommended in order to reduce the risk for side effects such as hypersensitivity reactions 
and nephrogenic systemic sclerosis.57,67 Dynamic brain MRI scans have reported that newly 
formed MS-lesions usually show a centrifugal (outwards) filling of contrast media, while 
subacute lesions more typically show an early ring enhancement with centripetal (inwards) 
filling.68 Reactivated chronic lesions typically display ring enhancement.69  
1.2.3 Lesion morphology and topography 
MS lesions are typically ovoid or rounded as they are centered along a venule and have 
certain predilection sites, illustrated in Figure 7 and 8. MS lesions are typically: 
• Periventricular: These lesions are centered around venous vessels radiating 
perpendicularly from the ventricles and the corpus callosum into the centrum 
semiovale. They can therefore have a finger-like appearance, a radiological sign 
called Dawson’s fingers.57 The surface of the corpus callosum adjacent to the lateral 
ventricles is affected by lesions in 55-95% of all MS patients.70  
• Juxtacortical: MS lesions commonly affect the short communicating fibers, called U-
fibers, that project tangentially alongside the cortex inbetween associated cortical 
areas and thus compose the white matter adjacent to the cortex.43  
• Infratentorial: Lesions below the cerebellar tentorium are common in MS and lesions 
in the brainstem and cerebellum are helpful in increasing the specificity of MS 
suspected white matter abnormalities.71,72 T2-weighted images have classically been 
considered to be more sensitive for infratentorial lesions than FLAIR images, but this 
may not be true for 3D FLAIR acquisitions. Detection of infratentorial lesions may 
also be affected by pulsation and flow artifacts.73 
 
Figure 7. Periventricular MS lesions in a “Dawson’s fingers” pattern (left), a juxtacortical lesion 
(middle, arrow) and a contrast-enhancing infratentorial lesion (right, arrow).  
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• Spinal: The spinal cord is also affected in MS and spinal lesions are mainly located in 
the cervical medulla.74 Spinal lesions are often symptomatic and tend to correlate 
relatively well with EDSS (due to EDSS’ focus on physical mobility), but there are 
also asymptomatic spinal lesions.75,76 These can be used as diagnostic clues as 
asymptomatic spinal lesions are uncommon in other diseases and may strengthen the 
radiological suspicion of MS in patients with equivocal brain white matter anomalies. 
However, spinal imaging is complicated by the small size and mobility of the spinal 
cord in combination with flow, pulsation and susceptibility artifacts.77  
• Optical nerves: About half of all MS patients experience at least one optical neuritis, 
which is also a frequent presenting symptom. Dedicated fat-suppressed coronal 
images of the optical nerves and chiasm should be obtained if there are visual 
symptoms.57,78  
Figure 8. MS lesion distribution in 50 RRMS patients projected on the Montreal Neurological 
Institute (MNI) standard space template. The colour scale represents the probability (range 1-55%) of 
finding MS lesions at the different sites.79 
 
1.2.4 The diagnostic role of MRI in MS  
The radiological classification of suspected MS lesions have been revised along with the 
clinical diagnostic criteria. Paty et al. defined the earliest radiological classification in 1988,80 
followed by Barkhof et al. in 1997, which was later refined by Tintoré et al. in 2000.81 The 
current MRI classification, defined by Swanton et al.,82 simplified the requirements for DIS 
while increasing the overall accuracy of the diagnostics, exemplified in Table 1.  
Table 1. Comparison of the two latest revisions of the radiological classifications for MS lesions. 
MS criteria McDonald 200529 McDonald 201025 
Radiological classification Barkhof-Tintoré81 Swanton71 
Demonstration of DIS  At least 3 out of:  
≥3 periventricular lesions  
≥1 juxtacortical lesion  
≥1 infratentoriell or spinal lesion 
≥1 contrast-enhancing or ≥9 lesions 
At least 2 out of:  
≥1 periventricular lesion 
≥1 juxtacortical lesion  
≥1 infratentoriell lesion 
≥1 spinal lesion 
Demonstration of DIT  - New lesion(s) ≥1 month after the 
initial clinical event 
- Contrast-enhancing lesion(s) ≥3 
months after the initial clinical event 
- New/contrast-enhancing 
lesion(s) on follow-up and/or 
- Concomitant asymptomatic 
contrast-enhancing lesion(s)  
Sensitivity, specificity82 60%, 88% 72%, 87% 
There are regional differences in MS that also have to come into consideration from a 
radiological perspective. For instance, Asian MS patients are typically older, have a lower 
incidence of oligoclonal bands and more commonly present with an optico-spinal form of the 
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disease. This means that the McDonald criteria have to be modified when applied to Asian 
patients and that the imaging protocols should also focus on optical nerve and spinal imaging 
in these patients.57  
Surveillance: MRI is used in clinical practice to monitor 
treatment response.57 MRI activity is defined as new, 
enlarging or contrast-enhancing lesions.30 Lack of activity 
indicates suppression of the inflammation and supports 
continuation of the current treatment, while activity may 
indicate a need for more frequent follow-ups or a change of 
therapy.57 MRI is also used to detect progressive multifocal 
leukoencephalopathy (PML), a rare but serious side effect of 
the drug natalizumab where there is an infection or re-
activation of JC virus in oligodendrocytes, a virus that many 
healthy persons carry in a dormant state. PML has a 
heterogenous MRI appearance but is often seen as large 
diffuse white matter lesions (see Figure 9) with restricted 
diffusion and may have contrast-enhancement and/or cyst-like appearance.83  
Treatment trials: MRI’s excellent ability to demonstrate disease activity is used to study the 
efficacy of MS drugs. MRI based measurements are used as the primary outcome in phase II 
studies and are important secondary endpoints in phase III trials. An illustration of the use of 
radiological outcome measures in MS trials is presented in Figure 10. T2 lesion load/volume 
and contrast-enhancing lesions are the two most commonly used measures. There are strong 
correlations between the effect of treatment on MRI activity and clinical relapses, supporting 
the rationale of using imaging surrogate markers.84 The trend towards lower relapse rates in 
MS patients and a decreasing number of untreated patients make clinical outcome measures 
harder to reach and highlights the importance of imaging biomarkers as outcome measures.67  
Figure 10. Frequency of MRI-based endpoints in phase I-IV clinical trials from 1993-2014 (88 
studies). The sizes of the circles represent the number of studies using the respective measurements at 
a certain trial time point. The largest circles (EDSS at month 0 and 3) represent 80 trials.85  
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Contrast-enhancing lesions 
 
T2-lesion load/volume 
 
Brain volume 
Figure 9. FLAIR of a MS patient 
with PML showing diffuse white 
matter changes (arrows). Image 
courtesy of Juha Martola. 
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Pathophysiological insights: MRI has in many cases overtaken autopsies and biopsies as the 
most important instruments to study the pathological processes in MS due to practical 
reasons, its non-invasive nature, reproducibility and repeatability.60 Non-conventional MRI 
techniques (see section 1.2.8) have also added to MRI’s multi-dimensionality and provided 
several new quantitative measures of focal and diffuse MS pathology.86  
Red flags: It is important to remember that white matter changes are frequent in healthy 
individuals and increase with age. They are also common in other diseases than MS. Mimics 
of MS are numerous and other causes for white matter abnormalities are, amongst others: 
normal aging, small-vessel disease, vasculitis, acute disseminated encephalomyelitis 
(ADEM), PML, encephalitis, neuroborreliosis (Lyme disease), sarcoidosis, toxic substances, 
leukodystrophies, Susac’s syndrome, cerebral autosomal-dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL), alcohol overconsumption and 
vitamin B12 deficiency.66  
Brain white matter changes should therefore be interpreted thoughtfully if the findings are 
atypical for MS or if there is a better alternative explanation for the patients’ presenting 
symptoms. Findings that should prompt caution in interpreting findings as MS include: 66 
• No brain lesions (i.e. only spinal and/or optical nerve lesions) 
• Extensive, symmetric or diffuse brain white matter changes 
• Sparing of the U-fibers and the corpus callosum 
• Contrast-enhancement of a majority of lesions 
• Extensive spinal lesions 
• Mass effect  
• Cerebrovascular lesions 
• A lack of dynamics (i.e. enlargement, shrinkage or disappearance of existing lesions 
or formation of new lesions) on follow-up imaging 
One of the most challenging tasks in clinical practice is differentiating whether white matter 
abnormalities are more likely to be MS lesions or ischemic-degenerative lesions. Main 
differences are summarized in Table 2.  
Table 2. Diagnostic clues for characterizing white matter changes. 
MS lesions Ischemic-degenerative lesions 
• Younger patients (15-40 years) 
• Often female 
• Periventricular lesions radiating from corpus 
callosum 
• Corpus callosal lesions and atrophy 
• Juxtacortical lesions 
• Infratentorial lesions often affect the middle 
cerebellar peduncles 
• Contrast-enhancing lesions 
• Dynamic lesions (see above) 
• Older patients (>40 years) 
• Male predominance 
• Lesions in watershed areas 
• Lack of lesions in MS predilection 
areas 
• Sparing of the U-fibers and corpus 
callosum 
• No contrast-enhancing lesions 
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1.2.5 Radiologically isolated syndrome  
Non-specific white matter anomalies on 
brain MRI are common incidental findings 
that increase in frequency with age. By 
definition, these unspecific changes are of 
unclear or no clinical significance.87 
Sometimes, however, there are incidental 
white matter anomalies with a radiological 
pattern similar to those seen in MS, in 
persons without typical MS symptoms.88  
The terminology for such incidental 
radiological findings has been diverse. In 
2009, two alternative definitions were 
proposed: radiologically isolated syndrome 
(RIS),89 and radiologically uncovered 
asymptomatic possible inflammatory-
demyelinating disease (RAPIDD).90 
Although none of the terms are perfect, 
RIS has become the convention.88 The RIS 
criteria as defined by Okuda et al. are 
presented in Table 3. In the past years RIS 
has become a hot topic in neurology 
mainly due to disagreements on the 
clinical management of these findings.91,92     
In contrast to MS, there are few 
epidemiological studies of RIS due to its 
recent definition. As elaborated in Study I, 
incidental MS findings have been described 
in large autopsy studies in Europe and 
North America with a frequency of 0.08-
0.2% in unselected materials,93–95 and 0.3% 
in patients with psychiatric disorders.96 The 
radiological equivalent of these findings, 
RIS, is likely to increase with the 
increasing use of MRI, seen in Figure 11.97  
The hospital-based frequency of RIS in 
Pakistan, a low prevalence region for MS,98  
has been reported to be as high as 0.7% in 
the ages of 15-40 years.99 In relatives of 
MS patients, the RIS frequency has been reported to be 2.9%.29  
Table 3. The Okuda criteria for RIS.89 
A Incidental white matter abnormalities in the CNS 
meeting the following MRI criteria: 
1. Ovoid, well-circumscribed and 
homogeneous foci with or without 
involvement of the corpus callosum 
2. T2 hyperintensities measuring >3mm and 
fulfilling Barkhof criteria (≥3 out of 4) for 
dissemination in space27 
3. CNS white matter anomalies not 
consistent with a vascular pattern 
B No historical accounts of remitting clinical 
symptoms consistent with neurologic dysfunction 
C The MRI anomalies do not account for clinically 
apparent impairments in social, occupational, or 
generalized areas of functioning  
D The MRI anomalies are not due to the direct 
physiologic effects of substances (recreational 
drug abuse, toxic exposure) or a medical condition 
E Exclusion of individuals with MRI phenotypes 
suggestive of leukoaraiosis or extensive white 
matter pathology lacking involvement of the 
corpus callosum  
F The CNS MRI anomalies are not better accounted 
for by another disease process 
 
Figure 11. MRI examinations per year per 1000 
inhabitants as reported by the Organisation for 
Economic Co-operation and Development.97  
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As found in Study I,88 and later 
confirmed by a multi-center study 
by the Radiologically Isolated 
Syndrome Consortium,100 about 
two thirds of persons with RIS 
will show a radiological 
progression with new, enlarging 
or contrast-enhancing lesions 
during follow-ups of five years. 
Meanwhile, one third will 
develop clinical symptoms and 
thereby convert to CIS or MS in 
the same time span, as seen in 
Figure 12. As such, RIS can be viewed as potential preclinical or subclinical stage of MS and 
is therefore an important area for future research to better understand MS 
pathophysiology.88,100  
1.2.6 Traditional radiological biomarkers  
The historically most commonly used MRI measurement is the T2 lesion count/load/burden, 
which has a modest correlation with the clinical expression of MS, particularly in late disease 
stages with high EDSS values.57,101,102 This discrepancy, called the clinico-radiological 
paradox,74 is likely attributed to a number of reasons:  
• Lesions in non-eloquent areas. Only every 5-10th MS lesion is symptomatic.78,103  
• Diffuse white matter changes are difficult to demarcate visually and changes in the 
normal-appearing white matter can only be quantified with non-conventional imaging 
methods.104  
• The low sensitivity for cortical MS lesions on standard MRI sequences.78,105  
• Lack of optical tract and spinal imaging in some MRI protocols for MS.57  
• The dual role of the immune system, involved in both de- and remyelination, meaning 
that inflammatory changes can be both destructive and reperative.60 
• Limitations of EDSS, the classical clinical outcome measure, as mentioned in section 
1.1.7.45  
• The plasticity of the brain, where some individuals are better able to compensate for 
losses in neuronal function.74,106 
Despite the aforementioned paradox, MRI does have a prognostic value in MS. Typical MS 
lesions carries a ten-year risk of converting from CIS to MS of around 80%, while the risk is 
only 20% in CIS patients without typical MS lesions.101,107 Longitudinal studies have shown 
that mainly T1 hypointense lesions are predictive of cognitive decline.47 Meanwhile, contrast-
enhancing lesions have low prognostic value in terms of predicting relapses and disability.108 
Overall, long-term longitudinal MRI studies are scarce, why there is a need for further studies 
to identify predictive radiological biomarkers in MS.47 
Figure 12. Kaplan-Meier chart visualizing the risk of clinical 
progression in RIS.100  
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1.2.7 Corpus callosum as an imaging biomarker  
The corpus callosum is an anatomical structure that connects the two cerebral hemispheres. It 
is the largest cerebral commissure and mainly consists of myelinated axons that provide inter-
hemispheric interaction.109 The corpus callosum is significantly affected in MS, both through 
focal lesions and through Wallerian degeneration caused by distant damage to fibers 
projecting through it.110 Corpus callosal morphology is therefore a logical choice for a MS 
imaging biomarker. As corpus callosum is easily visualized with MRI, there has been early 
interest in it for radiological MS research.111–113  
Technical developments in image processing and volumetry have shifted research focus to 
more advanced imaging techniques such as volumetry and non-conventional MR measures.86 
Studies have, however, shown that corpus callosal atrophy can actually be more strongly 
correlated with information processing speed than MS lesion volume.113–115 Corpus callosum 
morphology can distinguish MS patients from controls and differentiate subtypes of MS.116–
118 Furthermore, corpus callosum atrophy has been reported to be correlated with physical 
disability in 5 and 9 year long perspectives, and to predict conversion from CIS to MS.119–122   
There are manual, semi-automated and automatic methods for corpus callosum atrophy 
quantification, where manual methods or operator-supervised methods are considered to be 
the gold standard.123 The most commonly used manual methods are the corpus callosum area 
(CCA) and the corpus callosum index (CCI).124 These two measurements are further 
discussed in Methods, section 3.5.  
1.2.8 Volumetry  
The annual brain atrophy rate is around 0.1-0.3% in normal aging and substantially higher, 
0.6-1.0%, in MS regardless of the disease subtype.60,78 Brain atrophy is seen in all stages of 
MS and is more strongly correlated to physical disability than T2 lesion load. It also 
correlates with cognitive performance and health-related quality of life.74 Brain atrophy is 
therefore the most commonly used measure of neurodegeneration in treatment trials. Whole-
brain atrophy measures are unspecific and reflect many different aspects of the accumulating 
pathological changes in MS.78 Contributors to the tissue loss are neuronal damage with 
Wallerian degeneration and axonal loss with subsequent gliosis.60 It is important to 
remember, however, that changes in cerebral volume can also be due to physiological factors 
(hydration status), treatment with anti-inflammatory drugs (pseudo-atrophy with reductions 
of edema) and technical reasons (scanner and software differences).78  
Segmentations of grey matter and white matter are now commonly used in research and 
increase the specificity of the atrophy. Grey matter atrophy is closely associated with 
neuronal loss, reductions of synaptic density and loss of cortical connectivity, why it is 
strongly correlated to cognitive impairment.60 Segmentations of grey and white matter are 
most accurately performed on 3D T1-weighted sequences with near-isotropic resolution with 
a voxel size of around 1 mm3. A caveat is that white matter MS lesions may have a signal 
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intensity mimicking grey matter, which may bias the results. MS lesion segmentation and 
filling (replacing the lesions with white matter intensity) is therefore recommended.125  
Lesion segmentation, as exemplified in 
Figure 13, is complex and there are 
numerous different approaches to 
estimate the MS lesion volume (LV). 
Multi-channel approaches, using image 
registration of multiple sequence types 
including FLAIR are recommended to 
ensure accurate lesion delineation due 
to the heterogeneity of signal intensities 
of MS lesions.125 Manual lesion 
segmentation remains the gold 
standard.67 
An increasing use of 3D MRI sequences and an expanding variety of volumetric software 
reflect the growing interest in volumetric brain measurements in neuroscience research. 
Although the post-processing procedures have been facilitated by improved graphical user 
interfaces and reductions processing times, these quantitative biomarkers have yet to become 
implemented in the clinical workflow.86,104 Main reasons include lack of resources or time for 
image processing, reproducibility issues and difficulties in interpretation of the data on an 
individual basis.  
1.2.9 Non-conventional and emerging imaging techniques  
Many metabolic and molecular imaging methods are used exclusively in a research setting 
due to their complexity, technical limitations and costs. These methods are important in 
expanding our understanding of MS and can help us identify important disease mechanisms 
and novel MS treatment targets. The two first examples below, however, are new MRI 
sequences and alternative methods for reading the scans that are emerging and may come into 
clinical use in the near future.63  
Image registration methods can aid the radiological readings by better utilizing our 
commonly acquired MRI data. On example is subtraction MRI where follow-up scans are 
overlaid on baseline scans to increase sensitivity for lesional change and atrophy.126 Another 
application is FLAIR* where FLAIR sequences are registered to susceptibility weighted 
images, which increases the specificity of white matter abnormalities by identifying central 
venules in MS lesions.127  
Sequences for cortical lesion detection have given a renaissance to cortical MS pathology 
previously known from autopsy studies. These lesions are important as they increase the 
specificity of the diagnostic MRI criteria for MS.128 They are also independent predictors of 
two-year grey matter atrophy and worsening of physical disability.129 The two main new 
sequences are double inversion recovery (DIR), where a second inversion pulse for fat 
Figure 13. Axial FLAIR (left) and lesion segmentation 
(red, right) in a 28-year-old female with 12 years disease 
duration of RRMS. Lesion volume was 13 milliliters.  
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suppression is applied to a T2-FLAIR, and phase-
sensitive inversion recovery (PSIR) where phase 
information is used in the reconstruction of a T1-
weighted inversion recovery, as seen in Figure 14.105 
Arterial spin labeling (ASL) is an MRI technique 
that quantifies cerebral perfusion. Protons of the 
inflowing arterial blood are magnetically labeled and 
then interact with protons in the imaging slice, thereby 
changing the MRI signal proportionally to the 
perfusion. Acute MS lesions typically have increased 
perfusion, while reductions in perfusion are seen in chronic lesions, subcortical grey matter 
and normal-appearing white matter.60  
Functional MRI (fMRI) is sensitive to changes in the cerebral blood flow that indirectly 
reflect cortical activation in task-based paradigms or in a “resting” state. fMRI can be based 
on ASL or blood-oxygen-level dependent (BOLD) contrast imaging where the difference in 
magnetic properties of saturated and unsaturated hemoglobin is utilized. fMRI has 
consistently shown abnormal activation of accessory cortical areas compared to controls. 
These abnormal activation patterns change with the disease course and are thought to reflect 
adaptive mechanisms that limit the functional effects of structural damage.43 
Magnetic transfer ratio is an indirect measure of tissue integrity where a saturation pulse is 
applied with a frequency differing from the expected spectrum of free protons, called an off-
resonance pulse. This pulse mainly affects protons bound to macromolecules that typically 
relax faster than we can obtain a signal. There is, however, interactions between bound and 
free protons and some of this magnetization will be transferred to the free protons that we can 
image.130 The magnetic transfer ratio is strongly correlated to demyelination and axonal 
damage and quantifies tissue damage in normal-appearing white matter and before lesions 
become visible. The measurement is strongly correlated to mobility and cognitive function, 
but is only viable for comparisons on a group level and has limited reproducibility.43,78  
Diffusion tensor imaging (DTI) is used to study the 
integrity and major direction of white matter tracts by 
magnetically labeling protons and studying their 
diffusivity.60 DTI allows for tractography, illustrated in 
Figure 15,131 where the integrity of white matter tracts 
can be studied together with structural connectivity. DTI 
is a sensitive measure of axonal integrity with 
pronounced changes in focal lesions, intermediate 
changes in dirty-appearing white matter and more subtle 
changes in normal-appearing white matter.43 
Tractography has shown that tract abnormalities are only partly explained by MS lesion 
location, highlighting the role of diffuse MS pathology.47  
Figure 15. Whole-brain DTI based 
tractography.131 
Figure 14. Axial PSIR in a 49-year-old 
male MS patient visualizing a cortical 
lesion (arrow). 
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Magnetic resonance spectroscopy shows early metabolic changes in MS and can reveal 
diffuse tissue damage in MS that is not visible on conventional MRI. Reduced N-
acetylaspartate is a sensitive marker for neuronal degeneration/dysfunction and predicts brain 
atrophy.132 Demyelination leads to increased levels of choline, representing cell-membrane 
phospholipid turnover, and lipids such as myo-inositol.78 In active inflammation the levels of 
lactate and glutamate increase, suggesting a role for glutamate excitotoxicity.132 There are 
also increased concentrations of sodium in MS as a sign of neurodegeneration.63 
Positron emission tomography (PET) is a method where 
radioactive isotopes are coupled to a molecule of biochemical 
importance and administered intravenously, making it possible 
to visualize the distribution of the radioligand down to pico-
nano molar levels. PET reveals altered glucose metabolism 
and cerebral blood flow in MS and changes in 
neurotransmitter levels. It can also show de- and remyelination 
and has unveiled widespread microglial activation, 
independent from relapses, in white and grey matter as 
depicted in Figure 16.133  
Ultra-high field strength (7 T) is becoming increasingly 
available for research. The first human 7 T MRI scanner in 
Sweden was installed in Lund as a national research resource, inaugurated in May 2015. The 
high field strength offers increased signal-to-noise ratio that can be used to improve temporal 
or spatial resolution. There are also increased susceptibility effects that are advantageous for 
certain applications, but that also provide challenges in terms of inhomogeneities.134 
Myelin water imaging is a novel technique based on relaxometry where there is a separation 
of the MRI signal based on its relaxation times. The underlying theory is that protons bound 
in the myelin sheaths have faster relaxation times than those in extracellular and intracellular 
fluids and CSF.135 The proportion of the fast relaxing myelin-bound water has been validated 
as an in-vivo surrogate measurement of myelin.136 Myelin water imaging is a promising 
candidate for a specific MRI-derived biomarker in MS as it reflects clinical variability in MS 
and changes with disease progression,137 but there are still technical limitations and its full 
clinical potential remains to be studied.135   
 
Figure 16. 11C-PK11195 PET 
showing cortical microglial 
activation (arrows) in MS.133 
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2 AIMS OF THIS THESIS 
The overall purpose of this thesis was to describe neuroradiological aspects of multiple 
sclerosis, from early signs to late stages, with an emphasis on MRI findings, aiming to 
facilitate diagnosis and individualization of treatment and care for patients with RIS and MS.  
The specific objectives of each study were:  
Study I To identify relevant articles regarding incidental MRI findings suggestive of 
MS, summarize the nomenclature and current knowledge of such findings 
and to give recommendations for future studies.  
 
Study II To estimate the annual frequency of RIS at a university clinic in a region 
with a high incidence and prevalence of MS.  
 
Study III To compare the feasibility and performance of corpus callosum area and 
corpus callosum index as radiological biomarkers for cognitive and physical 
disability in MS. A secondary aim was to compare corpus callosum area and 
corpus callosum index to volumetric brain measurements in these regards.  
 
Study IV To study the progression of corpus callosal atrophy in MS and assess the 
longitudinal use of normalized corpus callosum area as a biomarker for 
cognitive and physical disability in MS.  
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3 MATERIALS AND METHODS  
3.1 ETHICAL CONSIDERATIONS  
Study I, consisting of a systematic-review, did not require ethical approval as it did not 
involve any participants, experimental procedures or management of sensitive personal data.  
The Regional Ethical Review Board in Stockholm approved Study II (registration number 
2011/1085-31/3) as well as Study III and IV (registration numbers 04-906/4 and 2012/858-
31/2). Written informed consent was obtained from all participants.  
3.2 PROCEDURES AND PARTICIPANTS  
Study I. This systematic review was performed according to the preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) statement on the 2nd of March 2012.138 The 
search strings, inclusion criteria and exclusion criteria were predefined, as detailed in the 
Supplementary appendix for Study I.88 The databases used were Embase, PubMed, Scopus 
and Web of Knowledge. Two raters (Tobias Granberg and Juha Martola) independently 
evaluated all abstracts and any discrepancies in inclusion/exclusion were decided by a third 
rater (Maria Kristoffersen-Wiberg). All articles included were read to full extent and their 
references were scrutinized to identify any additional studies of interest.  
Study II. In this retrospective study conducted in 2012, all brain MRI examinations 
performed at Huddinge sjukhus in 2001 were anonymously screened for white matter 
anomalies fulfilling the Okuda RIS criteria.89 The sample year was chosen due to the 
availability of digital storage of radiological and clinical data, and in order to investigate the 
10-year prognosis of identified RIS cases. Persons of interest in the study, where more 
clinical information was needed, were de-anonymized in order to obtain written informed 
consent for inclusion in the study and for reviewing their clinical patient charts.  
Study III and IV. In this 
longitudinal cohort study, 37 
MS patients were recruited from 
the outpatient clinic at the 
Department of Neurology, 
Huddinge sjukhus and followed 
with MRI, neurological 
assessment and neuro-
psychological testing from 1996 
with follow-ups in 2004 and 
2013. An age- and gender-
matched healthy control group 
was recruited at the last follow-up. A flow chart of the patient participation in the study is 
shown in Figure 17 and the demography of the participants is detailed in Table 4.  
Figure 17. Patient participation in the longitudinal study. 
Patients at entry in 1996
(37)
Deceased (5)
Bedridden (3)
MRI contraindication (3)
Declined participation (3)
Patients at follow-up in 2004
(37)
Patients at last follow-up in 2013
(23)
Controls in 2013
(23)
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Table 4. Demography of the participants in Study III and IV.  
 All patients 
1996 
Remaining 
patients*  
1996 
Remaining 
patients* 
2004 
Remaining 
patients* 
2013 
Controls 
2013 
N 37 23 23 23 23 
Sex, N, 
females/males  
26/11 18/5 18/5 18/5 18/5 
Age, years  42 (10) 39 (8.1) 48 (8.1) 57 (8.0)** 57 (7.2)** 
MS subtype, N, 
RR/SP/PP 
23/11/3 18/5/0 13/10/0 3/20/0 - 
Disease duration, 
years  
11 (8.5) 10 (6.9) 19 (6.8) 27 (6.9) - 
EDSS, median 
(range) 
4.5 (0.0-8.0) 3.5 (0.0-6.5) 5.0 (1.0-7.5) 6.0 (1.5-8.0) - 
DMT 65% 17% 52% 22% - 
*The 23 patients followed to 2013. **p = 0.95. Mean values if not otherwise specified. Standard 
deviations are reported in parenthesis. DMT = Disease Modifying Therapy, RR = Relapse-Remitting 
MS, SP = Secondary Progressive MS, PP = Primary Progressive MS.  
3.3 CLINICAL EVALUATIONS  
Study II. The clinical information in the 
referrals and, when needed, the clinical 
patient charts were evaluated by a 
medical doctor (Tobias Granberg) with 
the support of an experienced MS 
neurologist (Sten Fredrikson) according 
to the Okuda criteria as specified in 
Table 3.89 Special regards were taken to 
criteria B-F, i.e. that the white matter 
anomalies were not better explained by 
another disease process or substance and 
that there were no remitting neurological 
symptoms or impairments in daily 
activities. All possible RIS cases had 
been examined by a neurologist as part 
of the clinical work up. Final decisions 
on inclusion or exclusion based on 
Okuda criteria B-F were made by 
consensus of the two raters.   
Table 3 (reiterated). The Okuda criteria for RIS.89 
A Incidental white matter anomalies in the CNS meeting 
the following MRI criteria: 
1. Ovoid, well-circumscribed and homogeneous foci 
with or without involvement of the corpus callosum 
2. T2 hyperintensities measuring >3mm and fulfilling 
Barkhof criteria (≥3 out of 4) for dissemination in 
space.27 
3. CNS white matter anomalies not consistent with a 
vascular pattern 
B No historical accounts of remitting clinical symptoms 
consistent with neurologic dysfunction 
C The MRI anomalies do not account for clinically 
apparent impairments in social, occupational, or 
generalized areas of functioning  
D The MRI anomalies are not due to the direct 
physiologic effects of substances (recreational drug 
abuse, toxic exposure) or a medical condition 
E Exclusion of individuals with MRI phenotypes 
suggestive of leukoaraiosis or extensive white matter 
pathology lacking involvement of the corpus callosum  
F The CNS MRI anomalies are not better accounted for 
by another disease process 
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Study III and IV. Physical disability was scored according to EDSS by an experienced MS 
neurologist (Sten Fredrikson) at all time points (1996, 2004 and 2013). An experienced 
neuropsychologist (Gösta Bergendal) administered the neuropsychological testing at all three 
time points in conjunction with the MRI examinations. The main focus of the 
neuropsychological testing was SDMT.  
In 2013, a more comprehensive neuropsychological test battery was administered with 
additional testing including a verbal fluency test (FAS), Rey-Osterrieth complex figure test – 
copy and Rey auditory verbal learning test with encoding (0 min) and delayed recall (30 
min). The test battery was designed to reflect conceptually different cognitive functions with 
different neuroanatomical correlates, please see section 1.1.7 for further details on these tests. 
All raw test scores were converted to z-scores of normative data based on age, gender and 
educational level. Test results were defined as abnormal if the result deviated more than two 
standard deviations (SD) from the mean of the norm.139  
3.4 MAGNETIC RESONANCE IMAGING  
Study II. All brain MRI examinations were acquired at Huddinge hospital using two 1.5 T 
scanners, Siemens Vision and Symphony (Siemens Healthcare, Erlangen, Germany) with 
MRI protocols dedicated to the clinical queries in the referrals. Incidental white matter 
anomalies were in many cases further characterized with a dedicated MS protocol, especially 
in young patients where the MS incidence rate is high. The MS protocol was standardized in 
accordance with the “Stockholm prospective assessment of MS” study (STOP-MS) and the 
acquisition parameters are presented in Table 5.  
Table 5. MRI parameters of the standardized MS protocol in Study II.  
Sequence Plane Number of 
slices 
Slice 
thickness  
(mm) 
Repetition 
time  
(ms) 
Echo 
time 
(ms) 
Inversion 
time 
(ms) 
Flip 
angle 
(°) 
T1 
MPRAGE 
Axial 128 1.5 13.5 7 300 15 
PD/T2 TSE Axial 54 3.0 4761 22/90 - 180 
T2 TSE Sagittal 19 4.0 3500 96 - 180 
FLAIRGd Axial 27 5.0 9000 110 2500 180 
T1 SEGd Axial 27 5.0 570 14 - 90 
GdAcquired after intravenous administration of gadolinium-based contrast media. FLAIR = fluid 
attenuated inversion recovery, MPRAGE = three-dimensional magnetization prepared rapid 
acquisition gradient echo, PD = proton density, (T)SE = (turbo) spin echo.  
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Study III and IV.  Imaging was performed at Karolinska University Hospital on 1.5 T MRI 
scanners: General Electrics Signa (General Electric Healthcare, Milwaukee, USA) in 1996, 
Siemens Vision in 2004 and Siemens Avanto in 2013 (Siemens Healthcare, Erlangen, 
Germany). Care was taken to optimize comparability of the measurements over time by 
harmonizing the acquisition parameters, which are presented in detail in Table 6.  
Table 6. MRI parameters in Study III and IV.  
 Sagittal FSE/TSE T2 MPRAGE FLAIR 
Time point 1996 2004 2013 2004 2013 2004 2013 
Number of slices 11 19 19 160 160 19 126 
Slice thickness (mm) 5.0 4.0 4.0 1.4 1.4 5.0 1.4 
Gap between slices (mm) 0.0 0.4 0.4 - - 1.5 0.0 
In-plane resolution (mm) 1.0x1.0 1.0x1.0 1.0x1.0 1.0x1.0 1.0x1.0 1.0x1.0 1.0x1.0 
Repetition time (ms) 4000 3500 4290 1350 1910 9000 5000 
Echo time (ms) 76 96 103 7 3.08 110 411 
Inversion time (ms) - - - 3000 1100 2500 1800 
Flip angle (°) 90 180 150 15 15 180 120 
Number of averages 1 2 2 1 1 2 1 
FLAIR = fluid attenuated inversion recovery, FSE/TSE = fast/turbo spin echo, MPRAGE =  
three-dimensional magnetization prepared rapid acquisition gradient echo.  
3.5 RADIOLOGICAL EVALUATIONS  
Study II. All brain MRI examinations were first anonymized and systematically screened by 
a medical doctor (Tobias Granberg) with three years experience of neuroradiological research 
who had received training in assessing white matter changes by two neuroradiologists (Maria 
Kristoffersen-Wiberg and Juha Martola). The white matter anomalies were assessed 
according to the Barkhof classification,27 as stipulated by Okuda et al.89 Juxtacortical lesions 
were defined as involving the U-fibers, i.e. “touching the cortex”. In order to preserve a high 
sensitivity for possible RIS, the same rater also screened the clinical radiological readings in 
order to further identify any white matter anomalies suggestive of MS. All findings in the 
clinical radiological readings were further summarized in order to report on the disease 
panorama of the clinic. All plausible RIS cases according to the Okuda criteria,89 were re-
assessed by a neuroradiologist with long experience in MS (Juha Martola) according to the 
same classification, blinded to the clinical information and the clinical radiological readings.  
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Study III and IV. All radiological two-dimensional (2D) measurements of corpus callosum 
were performed on mid-sagittal MRI slices oriented by the inter-hemispheric fissure, the 
great cerebral vein (vein of Galen), and the cerebral aqueduct (aqueduct of Sylvius). The 
measurements were performed on standard radiological workstations using integrated 
measuring tools in the Picture Archiving Communicating System (PACS; IDS7, Sectra, 
Sweden). The measurements used in study III and IV were performed by a neuroradiologist 
(Juha Martola). Intra-rater agreement was studied at a second rating session 6 months later 
and inter-rater agreement was analyzed by comparing the ratings of the whole sample with 
those of a resident in radiology (Tobias Granberg) and an MD/PhD student (Sara Shams). All 
measurements were performed in a randomized order, blinded to the clinical data, previous 
ratings and each other’s ratings. 
The corpus callosum area was obtained by manual tracing of its outer contour. For the 
longitudinal evaluations in Study IV, the measurement was normalized (nCCA) to the 
intracranial surface area in the same slice.119 The corpus callosum index (CCI) was measured 
as defined by Figueira et al.117 Both of these measurements are illustrated in Figure 18.  
Figure 18. Corpus callosum measurements on mid-sagittal T2-weighted MRI. To the left is a 51-year-
old healthy female control and to the right a 52-year-old female MS patient. The corpus callosum 
area (left, turquoise) is normalized by dividing it by the intracranial surface (plum).124 Corpus 
callosum index (right, plum) is calculated by summing the anteroposterior length of the genu (aa’), 
the splenium (bb’) and the craniocaudal height of the body of corpus callosum (cc’), divided its length 
(ab) according to the equation: (aa’+bb’+cc’)/ab.117  
   
The above-mentioned manual radiological measurements were performed on T2-weighted 
images. However, in recent literature T1-weighted images are more frequently used for 
corpus callosum measurements, why the methods were also applied to sagittal reconstructions 
of the MPRAGE sequences. This complimentary comparison was quantified through an 
intra-rater agreement analysis of a resident in radiology (Tobias Granberg) across sequences.  
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3.6 VOLUMETRY  
In Study III and IV, the MPRAGE and FLAIR sequences from 2004 and 2013 were used for 
volumetry. All volumetric processing was quality controlled by a resident in radiology 
(Tobias Granberg) and image quality, with emphasis on motion artifacts and ghosting, was 
assessed prior to performing segmentations to ensure adequate image quality.  
The longitudinal stream of Freesurfer 5.3.0 (Harvard University, Boston, USA) was used to 
obtain brain tissue segmentations. Manual interventions to ensure accurate segmentations 
included removing misclassified meningeal tissue, adding control points to adjust intensity 
normalization failures and filling in white matter topological errors.  
MS lesion segmentations were performed using Lesion Segmentation Toolbox 1.2.3 
(Technische Universität München, Munich, Germany) for Statistical Parametric Mapping 8 
(University College London, United Kingdom) using a multi-channel approach with both 
MPRAGE and FLAIR sequences with a kappa value “0.3”, lesion belief map “GM”, 
resulting in the MS lesion volume (LV). All reported processing times are based on running 
above-mentioned software on a MacBook Pro (3 GHz Intel Core i7 processor, 8 GB DDR3 
1600 MHZ RAM) with OS X 10.8.5.  
The volumes of interest were the brain volume (BV), grey matter volume (GMV), white 
matter volume (WMV) and corpus callosum volume (CCV). The five sub-segmentations of 
corpus callosum provided by Freesurfer were summed to obtain the CCV, illustrated in 
Figure 19. The estimated total intracranial volume was used as a measurement of the 
intracranial volume (ICV). For the longitudinal evaluation in Study IV, all brain tissue 
measurements were normalized to the ICV, resulting in the brain parenchymal fraction 
(BPF), grey matter fraction (GMF), white matter fraction (WMF) and normalized lesion 
volume (nLV).  
Figure 19. Corpus callosum volume in a male MS patient with SPMS in 2004 (left: 2.2 milliliters) and 
2013 (right: 1.7 milliliters). In 2004 the patient was 38 years old with 15 years disease duration. 
EDSS scores were 7.5 at both time points. SDMT scores were -0.8 SD and -1.7 SD.  
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3.7 STATISTICAL ANALYSIS  
SPSS 22.0 (IBM, USA, 2013) was used to perform statistical analyses in Study III and IV. 
Normality of data was evaluated using the Shapiro-Wilk normality test. Group comparisons 
of parametric data were performed using independent or paired t-test, while non-parametric 
independent data were analyzed with the Mann-Whitney U test. Correlation analyses in 
parametric data were evaluated with Pearson correlation coefficient and non-parametric data 
(such as EDSS and LV) were analyzed using Spearman’s rho. In accordance with statistical 
convention, correlation coefficients (r) of 0.2-0.4 were considered weak, 0.4-0.6 moderate, 
0.6-0.8 strong and 0.8-1.0 very strong.140 Intra- and inter-agreement analyses for continuous 
measurements (such as corpus callosum area and index) were assessed using intraclass 
correlation coefficient (ICC) with a two-way mixed effects model for absolute agreement on 
single measures. In accordance with statistical convention, ICCs of < 040 were considered 
poor, 0.40-0.75 fair to good and >0.75 excellent.140 Classification accuracy in Study III was 
studied via the area under the curve (AUC) in receiver operating characteristic (ROC) curves 
with a nonparametric assumption of distribution. Statistical significance was pre-defined as 
an α-level of 0.05. Due to multiple comparisons in Study III and IV, Bonferroni corrections 
were applied. The corrected α-level was 0.006 for Study III and 0.007 for Study IV.  
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4 RESULTS  
4.1 STUDY I  
In total, 79 unique relevant publications were identified in the systematic literature search, out 
of which 60 articles were peer-reviewed articles. Incidental MRI findings suggestive of MS 
had a divergent terminology. In total, 12 patient cohorts and 6 case reports were identified 
from Brazil, France, Italy, Spain, Turkey and USA with 394 combined reported cases. Mean 
ages in the cohorts ranged from 30-42 years and the overall age range was 16-70 years. The 
female to male ratio of the reported cases was 2.0:1 (excluding a study focusing on the effects 
of pregnancy on RIS progression where there were naturally only female participants).  
As illustrated in Figure 20, the most 
common indication for the brain MRI 
unveiling the MS-like radiological findings 
was headache, composing nearly half of all 
reported cases. Two cohort studies 
provided neuropsychological test data, 
showing that thorough neuropsychological 
testing reveals subclinical cognitive 
impairments in persons with RIS. Persons 
with RIS showed similar but less 
pronounced deficits compared with MS 
patients in terms of information processing 
speed, verbal fluency, short term memory, 
cross-tapping and go/no-go test performance.141,142 Furthermore, it was shown that RIS 
patients have lesion distributions, lesion volumes and brain volumes,75,142–144 as well as 
spectroscopy findings similar to those found in MS.143  
Due to differences in the terminology and methodology used in the studies, the ability to 
perform a meta-analysis was limited. However, of all reported RIS cases roughly two thirds 
progressed radiologically, i.e. had new, enlarging or contrast-enhancing lesions on follow-up 
MRI examinations, during five-year follow-up. Meanwhile, about one third of the patients 
developed symptoms consistent with demyelinating disease and were thus diagnosed with 
MS (or CIS). Cervical spine lesions were identified as the most important predictor of clinical 
progression with other predictors being a high lesion load (especially in combination with 
abnormal CSF findings), contrast-enhancing lesions, cervical spine lesions, infratentorial 
lesions, younger age and pathological visual evoked potentials.  
We found that management of RIS was controversial with three alternative proposed 
approaches: wait (no intervention, instructing the patient to seek healthcare if symptoms 
develop), follow (regular clinical and radiological follow-ups with decreasing frequency) and 
treat (prescribing off-label DMT). In studies where treatment was reported, 10% of the 
patients received MS medications.  
Figure 20. Indications for the initial MRI unveiling 
RIS, N=394.  
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4.2 STUDY II  
In total 2105 individuals were examined with a brain MRI during the sample year. Ages 
ranged from 0 to 90 years, with a median age of 48 years. There were 1202 females (57%) 
and 903 males (43%) in the cohort. The results of Study II are illustrated in the flow chart in 
Figure 21 and the panorama of radiological findings in the cohort is summarized in Table 7. 
For more details on the step-by-step procedures and clinical details of the excluded patients, 
please see the original article. In the yearly sample, only one case of RIS was identified, 
equaling a frequency of 0.05% in the whole cohort. In the age range 15-40 years (661 
individuals), where MS is more common, the RIS frequency was 0.15%.  
The patient with RIS was a 43-year-old female who was healthy except for migraines. She 
had no previous symptoms suggestive of MS and no heredity for neurological diseases. She 
was referred for a brain MRI due to frequent migraines at work (1-3/week). The initial brain 
MRI demonstrated 15 T2-hyperintense lesions: 12 periventricular, 2 juxtacortical and 1 
contrast-enhancing, fulfilling the Barkhof classification for DIS.27 The MRI findings are 
illustrated in Figure 22. Thorough neurological examination provided normal findings. A 
lumbar puncture revealed oligoclonal bands and a raised IgG index. She was planned for a 
follow-up half a year later, but after three months she presented with dysesthesia and ataxia in 
the upper extremities. MRI showed three new brain lesions and a cervical lesion. She was 
diagnosed with MS and started on interferon β therapy. Over the coming years she continued 
to have Lhermitte’s sign but a benign course with only one distinct relapse in 10 years with 
lower extremity weakness. To date, she remains active and works full time.  
Figure 21 (left). Flow-chart illustrating the findings in Study II (N). Figure 22 (right). Axial T1-
weighted MRI illustrating a juxtacortical lesion (top) and the contrast-enhancing lesion (bottom). 
All individuals undergoing brain 
MRI at Huddinge sjukhus 2001
(2105)
Any white matter anomalies
(789)
Normal findings
 (542)
Fulfilling DIS
(326)
RIS
 (1)
Not fulfilling DIS 
(463)
Other pathology, see table 7
(774)
Known MS 
(185)
Exclusion, Okuda B-F criteria
(123)
Insufficient clinical data
(17)
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Table 7. Radiological findings in the yearly sample of brain MRIs at Huddinge hospital 2001. 
Individual patients may be represented in multiple categories  
Radiological findings Number of 
individual patients 
Within normal limits 542 
Cerebrovascular disorders 
- Infarctions  
- Vascular malformations, aneurysms, dissections and occlusions 
- Intracranial bleedings and contusions 
- Other 
326 
222 
73 
28 
3 
White matter and neurodegenerative disorders 
- Atrophy 
- Basal ganglia disorders 
- Hydrocephalus 
- Marked perivascular spaces 
- Possible inflammatory white matter changes 
- Unspecific or degenerative white matter changes  
1143 
285 
12 
20 
37 
356 
433 
Infectious, inflammatory and metabolic disorders 
- Intracranial infections  
- Optical neuritis 
- Metabolic disorders 
- Vasculitis 
- Other 
88 
32 
37 
4 
4 
11 
Neoplasms 
- Meningiomas 
- Intra-axial malignancies  
- Pituitary adenomas 
- Vestibular schwannomas 
- Unspecified or other types of neoplasms 
179 
44 
39 
31 
19 
46 
Cysts and malformations 
- Parenchymal, arachnoid and pineal cysts 
- Malformations or dysplasias  
- Pituitary gland cysts or disorders 
74 
42 
16 
16 
Sinonasal and orbital disorders 
- Sinusitis, mastoiditis, mucosal thickening 
- Other 
191 
187 
4 
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4.3 STUDY III  
Reliability and feasibility:  The inter-rater ICC for all three raters was 93% for CCA and 
94% for CCI. The intra-rater ICC for the neuroradiologist was 97% for CCA and 96% for 
CCI. When comparing measurements obtained on T1- and T2-weighted images the intra-rater 
ICCs were 93% for CCA and 90% for CCI. The mean time to obtain CCA measurements was 
43 seconds per subject and time point, compared with 18 seconds for CCI. Volumetric 
measurements took longer to acquire and edit, with a mean processing time of 14 hours and 
an average editing time of 33 minutes per subject and time point.  
Cognitive and physical disability: CCA was the measurement with the strongest correlation 
with both SDMT and EDSS. All corpus callosum-based measurements (CCA, CCI and CCV) 
had stronger correlations with SDMT than conventional volumetric measurements. 
Generally, all radiological measurements had less strong correlations with EDSS, with no 
more than moderate correlations. Further details are found in Table 8. 
Table 8. Radiological measurements cross-
sectional correlation with EDSS and SDMT. 
 
Correlation to  
SDMT (r, p) 
Correlation to  
EDSS (r, p) 
CCA 0.82, < 0.001* -0.56, < 0.001* 
CCI 0.73, < 0.001* -0.45, 0.001* 
CCV 0.72, < 0.001* -0.55, < 0.001* 
BV 0.50, 0.001* -0.45, 0.001* 
GMV 0.67, < 0.001* -0.50, < 0.001* 
WMV -0.16, 0.30 0.002, 0.99 
LV -0.69, < 0.001* 0.52, < 0.001* 
Correlation coefficients and p-values 
adjusted for age, sex and disease duration. 
*Correlations that remained significant after 
correction for multiple testing. BV = brain 
volume, CCA = corpus callosum area, CCI = corpus callosum index, corpus callosum volume,  
GMV = grey matter volume, LV = lesion volume, WMV = white matter volume.  
Classifying performance: Overall, the corpus callosum-based measurements were more 
accurate than the other radiological measurements in differentiating MS patients from 
controls. The overall accuracy (AUC) was 91% for CCA and 90% for CCI for all time points. 
The accuracy based on the two later time points (where volumetric data was available) is 
presented in Table 9. In the current population, a cut-off CCA of 6 cm2 separated patients 
from controls with a sensitivity of 79% and a specificity of 91%, as illustrated in Figure 23.  
The greatest accuracy in differing patients with a relapse-remitting subtype from progressive 
subtypes (PPMS and SPMS) was seen for LV, CCA and CCV, illustrated in ROC curves in 
Figure 23. Change of corpus callosum area with age.  
Linear regression lines with 95%-confidence intervals. 
The purple line illustrates the suggested 6 cm2 cut-off.  
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Figure 24. These results were corroborated in a leave-one-out cross-validation analysis, 
which can also be seen in Table 9.  
Figure 24. Accuracy in differentiation of MS patients from controls (left) and MS patients with 
progressive from relapse-remitting clinical courses (right). 
   
Table 9. Performance of the radiological measurements in differentiation tasks. 
 
Differentiating MS patients  
from controls 
Differentiating RRMS from 
progressive subtypes of MS 
 Accuracy Validation accuracy** Accuracy Validation accuracy** 
Corpus callosum area 95% 86 % 77% 72% 
Corpus callosum index 94% 84% 71% 62% 
Corpus callosum volume 89% 78% 77% 71% 
Brain volume 68% 63% 68% 62% 
Grey matter volume 71% 63% 70% 64% 
White matter volume 53% 49% 53% 47% 
Lesion volume - - 78% 63% 
RRMS = Relapse-Remitting MS. **Leave-one-out cross-validation analysis. 
 
  
 34 
4.4 STUDY IV  
Physical disability: Overall, there was a great span of disease duration (1.6-46 years) and 
EDSS scores (0.0-8.0) throughout the study. The physical disability increased moderately 
with the disease duration after adjustments for age and sex (r = 0.41, p < 0.001). With longer 
disease durations, the EDSS scores tended to plateau as visualized in Figure 25.  
Figure 25. Physical disability over disease duration for the 37 MS patients at all time points. Scatter 
plot with linear regression line (left) and individual EDSS scores connected by colored lines (right). 
 
Cognitive disability: All but four patients performed below the norms in at least one of the 
five tests in 2013. One patient chose not to participate in the testing, why 18 out of 22 (82%) 
were cognitively impaired. There were no difference in clinical or radiological characteristics 
between the MS patients with normal and subnormal cognitive performance, please see the 
original article for details.145 There were large individual differences in SDMT performance 
and SDMT had a weak negative correlation with disease duration (r = -0.37, p < 0.001). 
Corpus callosum measurements: Intra- and inter-rater ICCs for nCCA were excellent (both 
96%, p < 0.001). As specified in Table 10, nCCA differed significantly between patients and 
controls. In the control group, the nCCA was not correlated with age (r = -0.035, p = 0.88).  
Table 10. Comparison of the radiological measurements of MS patients and controls. 
 MS patients Controls p value 
N 23 23  
Normalized corpus callosum area 2.85 (0.79) 4.56 (0.59) < 0.001* 
Brain parenchymal fraction 67.4 (4.0) 70.0 (2.2)  0.007* 
Grey matter fraction 35.3 (4.4) 37.8 (1.7) 0.016 
White matter fraction 27.5 (4.1) 29.0 (2.0)  0.130 
Mean values in % with standard deviations in parenthesis.  
*Correlations that remained significant after correction for multiple testing. 
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The nCCA tended to decrease with increasing disease duration, corrected for age and sex  
(r = -0.18, p = 0.087). The mean decrease in CCA was 6.6 mm2 (1.2%) per year in the 23 
patients followed to 2013, with a higher atrophy rate between the two first time points  
(8.6 mm2, 1.6%) than the last two (4.4 mm2, 0.9%). The decrease in corpus callosal atrophy is 
seen in Figure 26. An individual example of corpus callosal atrophy is seen in Figure 27.  
Figure 26. Normalized corpus callosum area over time for the 37 MS patients at all time points. 
Scatter plot with a linear regression line (left) and individual corpus callosum measurements 
connected by colored lines in the graph (right). 
 
Figure 27. The corpus callosum area in 1996 (left, 606 mm2), 2004 (middle, 452 mm2) and 2013 
(right 418 mm2) in a female MS patient. At the first time point she was 34 years old, had a disease 
duration of 19 years with RRMS and an EDSS of 2.5. At the later two time pints she had converted to 
SPMS and had EDSS scores of 7.5 and 8.0. SDMT scores were -1.2, -2.0 and -2.3 SD respectively.  
The nCCA was strongly correlated with the information processing speed as measured by 
SDMT (r = 0.79, p < 0.001) and moderately correlated with the EDSS (r = -0.55, p < 0.001) 
after adjusting for age, sex and disease duration. As shown in Table 11, these correlations 
remained significant after correcting for multiple comparisons. The longitudinal correlations 
are featured in Table 12, where only nCCA in 2004 showed a strong correlation with the 
SDMT in 2013.  
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Table 11. Radiological measurements cross-sectional correlation with SDMT and EDSS. 
 
Correlation to  
SDMT (r, p) 
Correlation to  
EDSS (r, p) 
Normalized corpus callosum area 0.79, < 0.001* -0.55, < 0.001* 
Brain parenchymal fraction 0.16, 0.31 -0.32, 0.017 
Grey matter fraction 0.62, < 0.001* -0.45, 0.001* 
White matter fraction -0.34, 0.028 0.10, 0.48 
Normalized lesion volume -0.72, < 0.001* -0.49, < 0.001* 
 
Table 12. Radiological measurements at previous time points and their longitudinal correlation with 
SDMT and EDSS in 2013. 
 
All normalized values are reported in %. Correlation coefficients and p-values adjusted for age, sex 
and disease duration. *Correlations that remained significant after correction for multiple testing.  
In order to study the predictive correlation of the measurements, the correlations with the end 
measurements were adjusted for the SDMT and EDSS at each time point. This revealed no 
independently significant predictive correlations of any of the radiological measurements 
with the end SDMT/EDSS results, as detailed in Supplementary Table 2 of the original 
article.145 
Volumetry: BPF was the only volumetric measurement that differed significantly between 
MS patients and controls, as described in Table 10. The volumetric measurements overall 
showed stronger association with SDMT than EDSS. As detailed in Table 11, GMF and nLV 
were strongly correlated with SDMT and moderately correlated with EDSS after adjusting for 
age, sex and disease duration. From a longitudinal perspective, only nLV in 2004 showed a 
significant correlation with the SDMT in 2013. The results of all volumetric measurements at 
all time points are reported in Table 12. 
 
 Correlation to  
SDMT (r, p) 
Correlation to  
EDSS (r, p) 
Normalized corpus callosum area 1996 0.58, 0.015 -0.46, 0.021 
 2004 0.76, < 0.001* -0.48, 0.016 
Brain parenchymal fraction 2004 0.30, 0.24 -0.33, 0.20 
Grey matter fraction 2004 0.62, 0.008 -0.53, 0.028 
White matter fraction 2004 -0.020, 0.94 -0.054, 0.84 
Normalized lesion volume 2004 -0.64, 0.006* 0.27, 0.30 
  37 
Headaches 
Trauma Psychiatric 
disorders 
Endocrinological 
disorders 
Research control 
Epilepsy 
Radicular pain 
Tinnitus 
Medical screening  
/ follow-up Other 
5 DISCUSSION  
Study I: This systematic review was the first study to methodically summarize the 
knowledgebase regarding incidental MRI findings suggestive of MS. The results of the study 
have been important as they converged the terminology and the definition of this entity 
towards radiologically isolated syndrome, which is now the standard nomenclature.  
The most important finding in Study I was that one third of the persons with RIS develop 
typical MS symptoms, and thereby convert to MS, within five years. This finding, in 
combination with the consistent reports of neuropsychological and neuroradiological 
similarities between MS and RIS, clearly suggests that RIS in many cases is a preclinical 
stage of MS. These results have recently been corroborated in a large retrospective 
multicenter study, which also confirmed that asymptomatic cervical lesions are the most 
important predictor of clinical progression.100 Since the publication of Study I, the concept of 
RIS as subclinical/preclinical MS has been further underpinned by studies showing that: 
• Metabolic changes indicative of axonal degeneration are detected by magnetic 
resonance spectroscopy in persons with RIS, similar to what is expected in MS.146 
• Thalamic atrophy is more pronounced than reductions in WMV and GMV in RIS, 
which is in line with previous studies of CIS, pediatric MS and early RRMS.147  
• White matter integrity measured with DTI is reduced in RIS compared to healthy 
controls, but to a lesser degree than in RRMS. However, functional connectivity 
measured with resting-state fMRI is not affected in RIS, while there are changes in 
RRMS. This suggests that the CNS damage is not as pronounced in RIS as in MS 
and/or that that RIS patients have a functional reserve.148 
The above-mentioned multi-center study of RIS also reported similar indications for the MRI 
unveiling RIS, as displayed in Figure 28, highlighting headaches as the major indication.100  
Figure 28. Comparison of the MRI indications unveiling RIS in Study I (right, compiled data 
N=394),88 and in the multi-center study by Okuda et al. (left, N=451).100 
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The high frequency of headaches in RIS cases is noteworthy, but it remains unclear whether 
there is a causative relationship between the white matter anomalies and the headaches. 
Headaches are common in the general population and in MS, but headache prevalence 
estimates vary greatly, making it uncertain if headaches are more frequent in MS than in 
healthy individuals. Further complicating the issue is that headache is a known side effect of 
DMTs such as interferons,149 and that persons with migraine have a higher prevalence of 
white matter abnormalities.150 Epilepsy is another MRI indication in RIS of special interest 
since seizures have been described as an unusual presenting symptom of MS and that the 
prevalence of epilepsy is about three times higher in MS patients than in the general 
population.151 However, neither headaches nor epilepsy are considered typical MS symptoms 
and it is therefore hard to ascertain whether these correlations should be interpreted as an 
atypical onset of MS if the affected individuals later convert to MS.  
The subclinical cognitive deficits seen in RIS make it hard to distinguish the RIS entity from 
“cognitive MS”, which is a rare sort of MS where cognitive impairment or behavioral 
changes are the primary and predominant manifestation of the disease.152,153 However, by 
definition, persons with RIS do not fulfill the MS criteria and should not have cognitive 
deficits that affect their daily activities. It remains to be studied if persons with RIS that have 
subclinical cognitive deficits are more likely to develop cognitive MS.   
Another point of interest is the fact that 15% of the reported cases in the multi-center study 
had a family history of MS,100 since first degree relatives of MS patients have a 15-25 times 
higher risk of developing MS than the general population.11 The only study to date reporting 
on the prevalence of RIS in MS relatives showed that 2 out of 68 (2.9%) participants fulfilled 
the RIS criteria.154 However, MS heredity does not seem to be an independent predictor of 
conversion from RIS to MS,100 and prospective studies of relatives to MS patients are needed 
to determine the natural prevalence and significance of RIS in relatives of MS patients.  
The most surprising finding of Study I was that every tenth patient with RIS is treated with 
off-label immunosuppressive MS medications. As early treatment is beneficial in MS, it 
stands to reason that the same may be true for RIS that eventually evolves into MS. A caveat 
for this extrapolation is that it remains unclear if the clinical course of MS with a RIS onset 
differs from classical onset MS, which could possibly affect the risk-benefit analysis for 
treatment. Prospective follow-up of RIS is the recommended strategy by the MS Phenotype 
Group until treatment trials have been performed.30  
Strengths of the study were the systematic approach, following the PRISMA guidelines, and 
the use of multiple raters who individually analyzed the results of the literature searches. A 
limitation of the study was the semi-quantitative nature of the results as differences in 
terminology, methodology an possible overlaps of the described RIS cohorts hindered a 
precise meta-analysis to be conducted.  
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Study II: The main finding in this observational study was that the frequency of RIS was 
much lower than expected. RIS findings constituted just 0.05% of a yearly sample of brain 
MRI examinations at a tertiary hospital in the Stockholm region, which has a high incidence 
and prevalence of MS. Interestingly, the only case of RIS showed a fast conversion to MS, 
but then a relatively benign disease course.  
The incidence of RIS is expected to increase with MRI usage and the MS incidence. The low 
frequency of RIS findings is therefore somewhat counterintuitive when compared with the 
only previous epidemiological study of RIS, which was conducted in Pakistan, a region with 
low MS incidence and prevalence. In the same age group (15-40 years), we found a lower 
RIS frequency of 0.15% compared to 0.7% in Pakistan. One explanation for this discrepancy 
could be the fact that the awareness of MS and MS symptoms is higher in the general 
population and among doctors in high-incidence regions for MS. Unexpected MS findings 
would thus be less frequent. Differences in study methodology and MRI availability may also 
have contributed to the differences in results. 
When interpreting the results of Study II, there are two major limitations that have to be taken 
into account. One is the fact that the initial screening of the radiological data was not 
conducted by a radiologist, but instead by a trained rater (Tobias Granberg), who at the time 
of analysis was a medical student. Although all patients of interest were re-evaluated by a 
neuroradiologist, it can be argued that the use of a second rater or a rater with longer clinical 
experience could possibly have increased the number of identified patients of interest. 
Another limitation is the fact that the sample was taken from a university hospital in a region 
with high MS incidence and prevalence, which may not be generalizable to other regions or 
non-tertiary hospitals.  
In an effort to increase our understanding of the epidemiology of RIS, we decided to account 
for these limitations in a second study that we conducted in 2014, which is currently under 
review. A similar approach was used but the radiological screening was performed by a 
radiologist in a population-based sample containing all brain MRI’s performed in 
Västmanland county, Sweden, in 2013. The RIS incidence rate in Västmanland was found to 
be similar to our findings in Study II, suggesting that above-mentioned limitations may not 
have influenced the results substantially.  
Study III and IV: There are two major implications from the results of these two studies. 
One is that the results encourage us to refocus research and clinical interest in corpus 
callosum morphology because of its special strategic importance and its close association 
with physical and cognitive disability in MS. The second is that corpus callosum atrophy is 
easily quantifiable with excellent reproducibility with 2D measurements that can be obtained 
on conventional sequences within less than a minute by trained raters.  
Study III constituted the first comparative study of the two most commonly used 2D 
measurements of corpus callosum – corpus callosum area (CCA) and corpus callosum index 
(CCI). Both proved to have excellent repeatability and reproducibility across raters with 
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varying neuroradiological experience and across sequence types. The acquisition time for 
CCI was faster than for CCA (18 versus 43 seconds), while the necessary manual edits of the 
automatic volumetry were far more time-consuming. All corpus callosum measurements 
(CCA, CCI and CCV) were more closely associated with cognitive and physical disability 
than commonly used volumetric measurements (BV, WMV, GMV and LV), which is in line 
with previous studies.115,121,155 CCA consistently proved to be the measurement with the 
strongest relationship with the clinical parameters, both SDMT (r = 0.82, p < 0.001) and 
EDSS (r = -0.56, p < 0.001), after adjusting for age, sex and disease duration. CCA also had 
the highest accuracy in differentiating MS patients from controls (95%) and RRMS from 
progressive forms of MS (77%).  
Study IV showed that the corpus callosal atrophy rate decreased with increasing disease 
duration and that the nCCA was strongly correlated with SDMT and EDSS even during 
nearly two decades of follow-up. The plateauing corpus callosal atrophy and physical 
disability indicate that the underlying pathology in highly myelinated areas is more 
aggressive in the early phases of the disease, encouraging early treatment. This interpretation 
is supported by histopathological studies showing that the most extensive axonal damage 
occurs in the early phases of MS.156  
Interestingly, there was no correlation between nCCA and age in the healthy control group 
while the classic brain volumetric measurements tended to decrease with age. The relative 
resistance to age-dependent change is in line with previous studies.157–159 This suggests that 
corpus callosum morphology may be a sensitive marker for MS pathology, especially at 
higher ages/later disease stages.  
Discouragingly, none of the radiological measurements had an independent predictive value 
in terms of predicting the clinical outcome. The results did, however, show interesting trends 
indicating that predictive values may be seen in larger cohorts.  
The slightly better performance of CCA compared to CCV is somewhat surprising as 3D 
measurements are generally preferable in most brain quantifications. This may not be true for 
corpus callosum as volume-based corpus callosum measurements struggle with the issue of 
defining the mediolateral anatomical borders of corpus callosum. This is due to the fact that 
corpus callosum consists of white matter tracts projecting between the two hemispheres and 
is thus in continuity with the white matter in both cerebral hemispheres. This issue is avoided 
in cross-sectional 2D measurements and may be the reason that CCA performs better as a 
biomarker in our studies. The fact that CCA is a measurement of the whole cross-sectional 
area of corpus callosum while CCI mainly reflect atrophy in the three measuring points in the 
genu, body, and splenium may explain the difference in performance between CCA and CCI. 
The major strengths of the studies are the longitudinal perspective, where the cohort has been 
studied over 17 years, and the fact that the same experienced neurologist and 
neuropsychologist have performed the clinical assessments throughout the study. Another 
strong point is the use of a matched healthy control group for comparison. The results also 
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have a good generalizability as the studied cohort reflects different subtypes of MS, a wide 
range of disability levels and disease durations spanning over five decades.  
The studies provide data on the longterm clinical and radiological progression in MS, which 
is a rarity due to the limited availability of MRI two decades ago. The scarce MRI availability 
is also the cause of the studies’ relatively small sample size, which is a major limitation of the 
studies. The loss of participants to the last time point is unfortunately a natural effect of the 
long follow-up as most of the patients that we were unable follow to 2013 were deceased or 
too disabled to participate. Despite the few participants, the results were highly significant 
and remained so after correcting for known confounders and multiple comparisons. The 
classification performance in Study III also remained stable in cross-validation testing.  
Another limitation is that three different scanners were used due to the natural need for 
hardware upgrades at the radiological department. To compensate for this, efforts were made 
to harmonize imaging parameters over time and all imaging was performed on 1.5 T 
scanners. Freesurfer measurements furthermore have good reproducibility across different 
scanners and even across field strengths, especially when using the longitudinal processing 
stream, as we did.160 Normalizations for head size were also used when analyzing the data 
longitudinally in Study IV, as this is an effective way of reducing inter-scanner variability.125  
Possible confounders in neuropsychological testing are depression and fatigue, and a major 
limitation of study III and IV is that no tests were performed to diagnose these conditions. 
This was a conscious choice since the neuropathological test battery and the MRI protocol at 
the last time point took 2.5 hours and adding further testing was deemed too impractical and 
uncomfortable for the participants. It also remains unclear how findings of depression and/or 
fatigue should have been handled since their impact on neuropsychological testing is unclear, 
with conflicting results in the literature.46 It cannot arbitrarily be managed statistically and 
excluding patients with depression would both decrease the power of the study and limit the 
generalizability of the results as the lifetime risk of depression in MS is high.161  
Lastly, the effects of medication with MS drugs on the clinical and radiological assessments 
are hard to appreciate as the frequency and type of MS treatment naturally varied throughout 
the study.  
General discussion: The findings of this thesis support the idea that RIS can be the earliest 
sign of MS, a glimpse of the disease before clinical conversion to CIS or MS. Figure 29 is an 
illustration that conceptualizes the integration of RIS in the MS paradigm.  
Patients will enter the trajectory at different phases in the illustration. Some will enter with 
RIS if they have happened to have an MRI (due to other indications or atypical symptoms) 
before MS onset. Others will present as CIS or RRMS with typical MS-symptoms and 
relapses, with the majority of cases eventually reaching a progressive disease stage.  
SPMS and PPMS has been grouped together with the rationale that they have similar ages at 
onset of progression.21 This grouping is controversial as the subtypes differ substantially from 
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a clinical point of view. However, histopathologically and radiologically the PPMS do not 
seem to differ considerably from the other subtypes, although RRMS patients tend to have 
larger lesions.162,163 It is therefore argued that a primary-progressive disease course without 
disease activity could possibly reflect a later stage of the disease where there has been an 
occult inflammatory phase, maybe due to the clinico-radiological paradox (see section 1.2.6) 
or other individual differences. Whether PPMS patients have a subclinical inflammatory 
phase is debated, but there is data suggesting that many PPMS patients do have contrast-
enhancing lesions, especially in the early phases (<5 years disease duration) of their 
disease.164 Interestingly, about 10% of persons with RIS go on to develop PPMS and thereby 
lack a classical inflammatory phase of the disease.100  
Figure 29. An illustration of how RIS may be interpreted as part of the MS paradigm. 
 
In the illustration, there is a plateau of EDSS as seen in Study IV. This is consistent with data 
from the Swedish MS registry (see Figure 30). MS lesions have been reported to increase by 
about 5-10% per year,101 and the reported annual brain atrophy rates are around 0.6-1.0%.60,78 
Based on our last two time points the lesion volume only increased by 2.2% per year and the 
brain volume reduction was a mere 0.2% per year. This suggest that the accumulated damage 
has a biological upper limit as the disease reaches a state where there is less healthy tissue left 
to loose, which is why the MRI findings in the figure above eventually plateau. This concept 
is supported by previous studies that suggest that the threshold for the plateauing effect is 
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around the time that patients reach EDSS 4,102 after which the rate of progression of physical 
disability is quite similar for patients with relapse-remitting and progressive onset.165  
Figure 30. An illustration of all registered EDSS scores of MS patients in Stockholm in the Swedish 
MS registry with a locally weighted scatterplot smoothing regression line. Image courtesy of Leszek 
Stawiarz at the Swedish Neuro Registries.  
In order for the RIS concept to gain further traction it is important that the diagnostic criteria 
are intuitive. An aspect that is rarely discussed in terms of RIS is the complexity of the Okuda 
criteria. These issues are discussed in detail below.  
• A corner-stone issue is that the findings in the current definition have to be incidental. 
This requirement makes it impossible to prospectively study RIS in general 
populations or in relatives of MS patients as the findings are then not truly incidental. 
• The phrasing of “remitting clinical symptoms consistent with neurologic dysfunction” 
is imprecise with a lack of clarity in terms of what indications for MRI are to be 
accepted within the RIS entity.   
• The impact on the activities of daily life (criterion C) is hard to evaluate. It also seems 
likely that even subclinical cognitive impairment in RIS may discreetly affect 
everyday life activities.   
• Clinical findings suggestive of MS in neurological examinations are not mentioned. It 
remains an open question whether it is reasonable to classify a symptomless person 
with clear neurological findings suggestive of MS as having RIS.  
• The concept of “no better explanation” is diffuse and met in several different criteria: 
A3, D, E and F.  
• The DIS classification (A2) is not in line with modern MS diagnostic criteria. This 
aspect is of special importance as the choice of DIS classification may decrease or 
increase the incidence and prevalence of RIS as well as the proportion of persons that 
will eventually convert to MS.  
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• The concept and significance of MRI evidence of DIT is not mentioned. This is of 
importance as contrast-enhancing lesions and dynamics with new lesions are more 
suggestive of MS than ischemic-degenerative white matter abnormalities.  
• Formulations could be more consise. An example is the redundancy in A1: “with or 
without involvement of the corpus callosum”.  
A new simplified RIS definition is therefore hereby proposed:  
Table 13. Proposition for new RIS criteria. 
A MRI findings fulfilling the current diagnostic MRI criteria for DIS.* 
B No symptoms or neurological findings typical for MS.** 
C The findings should not be more likely or better explained by 
another disease process, comorbidities or substances*** 
*Currently the 2010 McDonald criteria.25  
**Symptoms should be interpreted with the consultation of an experienced MS neurologist. Only 
symptoms that do not render a CIS or MS diagnosis, following a thorough physical neurological 
examination, are accepted.  
***The concept of “no better explanation” has been thoroughly discussed by Charil et al.66 
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6 CONCLUSIONS  
In summary, the first two studies of this thesis showed that unexpected brain MRI findings 
suggestive of MS are relatively uncommon in a region with a high prevalence and incidence 
of MS. These incidental radiological findings, which are preferably called radiologically 
isolated syndrome, are despite of this of clinical importance since persons with RIS are at 
high risk of developing MS. RIS is thus in many cases a preclinical stage of MS. RIS is 
therefore conceptually important to study since it may give an insight into the earliest stages 
of MS and why some individuals have no or atypical initial MS-symptoms.  
The second two studies of this thesis describe the progression of corpus callosal atrophy over 
17 years in a cohort of MS patients with disease durations spanning over nearly five decades, 
thereby including both early and late stages of the diseases. Novel findings include that the 
corpus callosum atrophy rate decreases with the disease duration and that CCA remains the 
preferred method for studying corpus callosal atrophy, even though new methods such as CCI 
and CCV have been introduced. The studies add to the growing body of evidence that corpus 
callosum atrophy is a more sensitive MRI biomarker than classical volumetric measurements. 
This suggests that CCA may be a suitable quantitative paraclinical biomarker for cognitive 
and physical disability in MS research and possibly in clinical practice since it is a fast 
method with excellent reproducibility.  
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7 FUTURE ASPECTS 
Although RIS has become a hot topic in the MS field, there is still work that needs to be done 
before RIS can be widely accepted as a preclinical and/or subclinical stage of MS and 
integrated into the MS classification tree. The definition of RIS has to be simplified and 
harmonized with the current diagnostic criteria for MS. The concept of “no better 
explanation” also has to be concretized to preserve a high specificity of RIS in terms of the 
risk for conversion to MS.  
Large prospective studies will have to show whether persons with RIS are more likely to 
have a similar or more benign clinical course of MS and the rationale for treating RIS with 
MS drugs. Hopefully, we will soon be able to tell if we can prevent or delay the conversion of 
RIS to MS as the first treatment trial for RIS is already planned.166 The relative sparsity of 
RIS encourages collaborative research efforts. The findings of this thesis and other RIS 
studies can aid us in constructing guidelines for management of RIS, preferably on a national 
or international level, in order to standardize the care for persons with RIS.  
The new therapeutic options in MS have created a need for prompt diagnosis and good 
predictors of the disease course to tailor the treatment for optimal results. Radiological 
practice has to implement new quantitative methods to respond to this need. There are many 
emerging imaging techniques (see 1.2.9) that may prove to be specific and robust enough for 
clinical use. Until then, measurements of corpus callosum atrophy could be a favorable 
approach for improving the diagnostics and surveillance in MS. 
CCA is a viable option due to its excellent reproducibility and that it can be performed by 
trained raters. The possibility to apply CCA to previously acquired sagittal 2D data also 
provides an opportunity to make use of previously acquired data in a way that is not possible 
with volumetry. The findings regarding CCA are therefore likely to be welcomed by research 
groups that are in need of quantitative MRI biomarkers but do not have the resources for 
volumetric analyses.  
Despite the practicality of CCA it may still prove challenging to implement it in a clinical 
setting as the method requires a short introduction and would be additional work for the rater 
in the clinical workflow. Cut-off values for different degrees of corpus callosal atrophy would 
also be necessary for interpretation on an individual level. The suggested 6 cm2 CCA value 
will have to be validated in other cohorts. An attractive option for clinical use that we are 
currently exploring is the development of a visual rating scale for corpus callosal atrophy 
where the visual interpretation could be complemented with CCA measurements in uncertain 
cases. 
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